Ricardo Vilain
Overview
Explore the profile of Ricardo Vilain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
376
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holmes A, Thant A, Correy R, Vilain R
Pathology
. 2022 Jul;
55(1):161-163.
PMID: 35843757
No abstract available.
2.
Mind Over Matter: Confronting Challenges in Post-Mortem Brain Biobanking for Glioblastoma Multiforme
Griffin C, Vilain R, King S, Nixon S, Gooley A, Bray S, et al.
Biomark Insights
. 2022 Feb;
16:11772719211013359.
PMID: 35173408
Over the past 10 years, there has been limited progress for the treatment of brain cancer and outcomes for patients are not much improved. For brain cancer researchers, a major...
3.
Ng R, Eliezer D, Vilain R, Kamien B, Deshpande A
Pediatr Dev Pathol
. 2019 Apr;
22(5):486-491.
PMID: 30935272
Menkes disease (MD) usually presents in infancy with respiratory and neurological complications. Severe isolated vasculo-connective tissue involvement in infancy is rare, and hence the precise and timely diagnosis is difficult....
4.
Holtkamp L, Wang S, Wilmott J, Madore J, Vilain R, Thompson J, et al.
Ann Surg Oncol
. 2017 Oct;
24(Suppl 3):660.
PMID: 29079922
No abstract available.
5.
Madore J, Strbenac D, Vilain R, Menzies A, Yang J, Thompson J, et al.
Clin Cancer Res
. 2016 Mar;
22(15):3915-23.
PMID: 26960397
Purpose: Understanding why some melanomas test negative for PD-L1 by IHC may have implications for the application of anti-PD-1 therapies in melanoma management. This study sought to determine somatic mutation...
6.
Beckers R, Selinger C, Vilain R, Madore J, Wilmott J, Harvey K, et al.
Histopathology
. 2015 Nov;
69(1):25-34.
PMID: 26588661
Aims: Triple-negative breast cancer (TNBC) patients generally have a poor outcome; there is a pressing need to identify more effective therapeutic strategies. Clinical trials targeting programmed death 1/programmed death ligand...
7.
Holtkamp L, Wang S, Wilmott J, Madore J, Vilain R, Thompson J, et al.
Ann Surg Oncol
. 2015 May;
22(9):2972-7.
PMID: 25990968
Background: Nonsentinel lymph nodes (NSLNs) are rarely involved in patients with minimal volume melanoma metastases in sentinel lymph nodes (SLNs). Therefore, it has been suggested that completion lymph node dissection...
8.
Luk P, Vilain R, Crainic O, McCarthy S, Thompson J, Scolyer R
Australas J Dermatol
. 2015 Apr;
56(3):227-31.
PMID: 25827527
The recommended initial management for suspected melanoma is excisional biopsy. The use of partial biopsies of melanocytic tumours poses potential problems including misdiagnosis due to either unrepresentative sampling or the...
9.
Kakavand H, Wilmott J, Menzies A, Vilain R, Haydu L, Yearley J, et al.
Clin Cancer Res
. 2015 Jan;
21(14):3140-8.
PMID: 25609064
Purpose: To evaluate the expression of tumor PD-L1 and changes in tumor-infiltrating lymphocyte (TIL) populations in patients with metastatic melanoma treated with targeted MAPK inhibitors. Experimental Design: Ninety-three tumors were...
10.
Vilain R, Wilmott J, Scolyer R
Pigment Cell Melanoma Res
. 2014 Jun;
27(5):696-7.
PMID: 24890897
No abstract available.